Last reviewed · How we verify
NCT03185325
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma
trial testing bone marrow puncture and venous blood samples in Non Hodgkin Lymphoma in 62 participants. Completed in 24 December 2019.
24 April 2019
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 62 |
| Start date | 10 March 2018 |
| Primary completion | 24 April 2019 |
| Estimated completion | 24 December 2019 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- bone marrow puncture and venous blood samples
- venous blood samples
Conditions studied
- Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →
Sponsor
Assiut University
Who can join
Eligibility, any sex, with Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lymphomas are hematological malignancies, which are divided into non-Hodgkin lymphoma and Hodgkin lymphoma. Non hodgkin lymphoma is a lymphoma-derived malignancy that makes up about 90% of all malignant lymphoma. According to its origin, non hodgkin lymphoma is classified into B-cell non hodgkin lymphoma and T-cell non hodgkin lymphoma. The most common types are follicular lymphoma, and diffuse large B-cell lymphoma. Lymphomas are types of cancer that develops from lymphocytes, a type of white blood cell. Diagnosis is by examination of a bone marrow or lymph node biopsy. Non hodgkin lymphoma mortality has increased in recent years and has become the seventh most frequently occurring cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03185325
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07016165 — Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Maligna · Phase 4 · recruiting
- NCT06622226 — A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · Phase 1 · active not recruiting
- NCT06522932 — PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy · Phase 1 · recruiting
- NCT06116110 — Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03185325 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 13 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03185325.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing